Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR)

INTRODUCTION: With the approval of natalizumab in Europe in 2006, the Austrian Multiple Sclerosis Therapy Registry (AMSTR) was established. Here, we present data from this registry about effectiveness and safety of natalizumab in patients treated up to 14 years. PATIENTS/METHODS: Data retrieved from...

Descripción completa

Detalles Bibliográficos
Autores principales: Monschein, Tobias, Dekany, Sarinah, Zrzavy, Tobias, Ponleitner, Markus, Altmann, Patrick, Bsteh, Gabriel, Kornek, Barbara, Rommer, Paulus, Enzinger, Christian, Di Pauli, Franziska, Kraus, Jörg, Berger, Thomas, Leutmezer, Fritz, Guger, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344989/
https://www.ncbi.nlm.nih.gov/pubmed/37074388
http://dx.doi.org/10.1007/s00415-023-11686-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344989/
https://www.ncbi.nlm.nih.gov/pubmed/37074388
http://dx.doi.org/10.1007/s00415-023-11686-2

Ejemplares similares